Profile data is unavailable for this security.
About the company
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2008
- Employees--
- LocationMedicus Pharma Ltd300 Conshohocken State Rd., Suite 200CONSHOHOCKEN 19428United StatesUSA
- Phone+1 (610) 540-7515
- Fax+1 (905) 681-1925
- Websitehttps://medicuspharma.com/
More ▼
Mergers & acquisitions
| Acquired company | MDCX:NAQ since announced | Transaction value |
|---|---|---|
| Antev Ltd | -71.90% | 75.00m |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural Alternatives International Inc | 134.44m | -11.88m | 19.21m | 293.00 | -- | 0.2783 | -- | 0.1429 | -1.99 | -1.99 | 22.52 | 11.17 | 0.845 | 4.35 | 7.36 | 458,839.60 | -7.47 | 0.4593 | -9.15 | 0.5479 | 8.50 | 12.75 | -8.84 | 0.4296 | 1.01 | -2.56 | 0.1408 | 0.00 | 14.12 | 1.78 | -88.10 | -- | -4.46 | -- |
| CASI Pharmaceuticals Inc | 26.85m | -49.38m | 19.52m | 233.00 | -- | -- | -- | 0.7271 | -2.98 | -2.98 | 1.62 | -1.85 | 0.6096 | 1.60 | 4.22 | 115,218.90 | -107.02 | -36.27 | -277.91 | -51.90 | 53.68 | 57.36 | -175.56 | -124.01 | 0.236 | -13.27 | -- | -- | -15.77 | 47.19 | -45.62 | -- | -55.67 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 20.76m | 217.00 | -- | 0.1459 | -- | 6.53 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Nutraproducts Inc | 0.00 | -821.94k | 20.92m | 0.00 | -- | 3.50 | -- | -- | -1.31 | -1.31 | 0.00 | 0.2973 | 0.00 | -- | -- | -- | -513.70 | -1,177.23 | -740.45 | -- | -- | -- | -- | -- | -- | -385.17 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Dare Bioscience Inc | 27.69k | -17.46m | 24.01m | 21.00 | -- | 8.19 | -- | 866.95 | -1.92 | -1.92 | 0.0029 | 0.2052 | 0.0011 | -- | 0.0624 | 1,318.57 | -71.56 | -91.64 | -241.96 | -243.93 | 127.70 | -- | -63,069.55 | -1,024.05 | -- | -156.39 | 0.7177 | -- | -99.65 | -- | 86.56 | -- | -- | -- |
| Aytu Biopharma Inc | 63.70m | -13.31m | 24.69m | 82.00 | -- | 0.9839 | -- | 0.3876 | -2.27 | -2.24 | 5.93 | 2.34 | 0.529 | 1.89 | 2.26 | 776,780.50 | -11.05 | -26.47 | -23.44 | -47.32 | 67.56 | 60.56 | -20.90 | -52.54 | 1.08 | 0.3443 | 0.5398 | -- | 1.84 | 19.16 | -13.27 | -- | -- | -- |
| TherapeuticsMD Inc | 2.80m | 73.00k | 25.35m | 1.00 | 350.96 | 0.9236 | 55.10 | 9.07 | 0.0062 | 0.0261 | 0.2419 | 2.37 | 0.0715 | -- | 0.8002 | 2,796,000.00 | 0.1867 | -42.65 | 0.2169 | -112.14 | -- | -- | 2.61 | -193.47 | -- | -5,240.00 | 0.00 | -- | 35.25 | -48.72 | 69.97 | -- | -- | -- |
| Medicus Pharma Ltd | -100.00bn | -100.00bn | 27.37m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0434 | -- | -- | -- | -- | -- | -361.95 | -- | -- | -- | -- | -- | -- | -- | -- | 1.13 | -- | -- | -- | -109.90 | -- | -- | -- |
| SCYNEXIS Inc | 2.93m | -25.30m | 28.97m | 28.00 | -- | 0.7951 | -- | 9.88 | -0.5107 | -0.5107 | 0.0593 | 0.8683 | 0.0391 | -- | 0.5776 | 104,714.30 | -33.71 | -20.51 | -43.65 | -24.97 | 33.32 | -- | -862.89 | -64.82 | -- | -- | 0.00 | -- | -97.33 | 98.68 | -131.75 | -- | -- | -- |
| Hyperion DeFi Inc | 345.32k | -26.40m | 29.32m | 13.00 | -- | 0.3503 | -- | 84.89 | -20.32 | -20.32 | 0.0385 | 9.88 | 0.0065 | -- | 1.06 | 26,563.08 | -48.31 | -102.28 | -59.47 | -168.53 | -798.11 | 60.58 | -7,385.51 | -856.97 | -- | -- | 0.0976 | -- | 1,412.93 | -- | -82.75 | -- | -0.6271 | -- |
| BioXcel Therapeutics Inc | 752.00k | -68.21m | 29.96m | 37.00 | -- | -- | -- | 39.84 | -10.41 | -10.41 | 0.1023 | -4.45 | 0.016 | 0.9718 | 501.33 | 20,324.32 | -145.62 | -76.45 | -449.90 | -88.28 | -28.19 | -- | -9,070.61 | -14,760.23 | 1.16 | -3.25 | 5.40 | -- | 64.20 | -- | 66.71 | -- | -- | -- |
| Kyntra Bio Inc | 8.30m | -131.13m | 30.34m | 225.00 | -- | -- | -- | 3.66 | -32.49 | 53.34 | 2.05 | -4.21 | 0.0413 | -1.47 | 0.421 | 36,880.00 | -64.00 | -39.47 | -260.98 | -61.33 | 345.69 | 90.21 | -1,548.18 | -199.02 | 3.60 | -- | 0.5269 | -- | -36.71 | -35.07 | 52.60 | -- | -45.94 | -- |
| United-Guardian Inc | 10.06m | 1.96m | 32.85m | 24.00 | 16.76 | 3.10 | 15.92 | 3.27 | 0.4266 | 0.4266 | 2.19 | 2.30 | 0.7911 | 3.82 | 7.58 | 419,180.40 | 15.41 | 26.91 | 17.85 | 31.16 | 50.60 | 54.16 | 19.48 | 26.97 | 6.16 | -- | 0.00 | 92.34 | 11.91 | -2.18 | 25.94 | -7.35 | 30.65 | -8.64 |
| Celularity Inc | 40.58m | -80.71m | 33.74m | 123.00 | -- | -- | -- | 0.8315 | -3.34 | -3.34 | 1.69 | -0.7121 | 0.3339 | 6.14 | 5.24 | 329,902.40 | -66.35 | -23.42 | -158.76 | -26.83 | 50.61 | -- | -198.75 | -294.70 | 0.123 | -6.57 | 2.01 | -- | 138.11 | -- | 70.51 | -- | -- | -- |
| Healthy Extracts Inc | 3.59m | -1.17m | 33.74m | 2.00 | -- | 1.40 | -- | 9.40 | -0.3195 | -0.3195 | 0.9095 | 1.43 | 0.2505 | 1.42 | 140.67 | 1,794,555.00 | -8.19 | -61.21 | -9.09 | -111.60 | 52.37 | 51.30 | -32.71 | -82.01 | 0.6491 | -2.84 | 0.0421 | -- | 25.24 | 32.99 | 66.01 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Medicus Pharma Ltd's reporting currency: US Dollar USD
9.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Interchange Capital Partners LLCas of 31 Dec 2025 | 1.59m | 7.20% |
| Yorkville Advisors Global LPas of 30 Sep 2025 | 230.00k | 1.04% |
| Private Advisor Group LLCas of 30 Sep 2025 | 151.50k | 0.69% |
| The Bryn Mawr Trust Co. (Investment Management)as of 30 Sep 2025 | 25.62k | 0.12% |
| Brave Asset Management, Inc.as of 31 Dec 2025 | 20.00k | 0.09% |
| LPL Financial LLCas of 30 Sep 2025 | 18.75k | 0.09% |
| May Hill Capital LLCas of 30 Sep 2025 | 17.81k | 0.08% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 14.96k | 0.07% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 14.00k | 0.06% |
| UBS Securities LLCas of 31 Dec 2025 | 13.17k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
